Robin  Sherrington net worth and biography

Robin Sherrington Biography and Net Worth

Dr. Sherrington has served as our Executive Vice President, Strategy & Innovation since March 2019. Dr. Sherrington previously served as our Executive Vice President, Business & Corporate Development since March 2018, as our Senior Vice President, Business & Corporate Development since February 2012, as our Vice President, Business & Corporate Development from January 2010 to February 2012, and has held various positions in business development and other departments since joining us in March 2001. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001. Dr. Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. Prior to 1996 Dr. Sherrington was a post-doctoral fellow at University of Toronto and received his Ph.D. from the University College London, and his B.Sc. with honors from University of Reading.

What is Robin Sherrington's net worth?

The estimated net worth of Robin Sherrington is at least $312,825.50 as of March 7th, 2024. Dr. Sherrington owns 8,398 shares of Xenon Pharmaceuticals stock worth more than $312,826 as of June 14th. This net worth estimate does not reflect any other investments that Dr. Sherrington may own. Additionally, Dr. Sherrington receives an annual salary of $351,670.00 as EVP at Xenon Pharmaceuticals. Learn More about Robin Sherrington's net worth.

How old is Robin Sherrington?

Dr. Sherrington is currently 63 years old. There are 6 older executives and no younger executives at Xenon Pharmaceuticals. The oldest executive at Xenon Pharmaceuticals is Ms. Shelley McCloskey B.A., Executive Vice President of Human Resources, who is 64 years old. Learn More on Robin Sherrington's age.

What is Robin Sherrington's salary?

As the EVP of Xenon Pharmaceuticals Inc., Dr. Sherrington earns $351,670.00 per year. There are 4 executives that earn more than Dr. Sherrington. The highest earning executive at Xenon Pharmaceuticals is Ms. Sherry Aulin, Chief Financial Officer, who commands a salary of $3,030,000.00 per year. Learn More on Robin Sherrington's salary.

How do I contact Robin Sherrington?

The corporate mailing address for Dr. Sherrington and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Robin Sherrington's contact information.

Has Robin Sherrington been buying or selling shares of Xenon Pharmaceuticals?

Robin Sherrington has not been actively trading shares of Xenon Pharmaceuticals in the last ninety days. Most recently, Sherrington Robin sold 7,137 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a transaction totalling $330,300.36. Following the completion of the sale, the executive vice president now directly owns 8,398 shares of the company's stock, valued at $388,659.44. Learn More on Robin Sherrington's trading history.

Who are Xenon Pharmaceuticals' active insiders?

Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Xenon Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 56,517 shares worth more than $2,346,560.56. The most recent insider tranaction occured on March, 7th when EVP Sherrington Robin sold 7,137 shares worth more than $330,300.36. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.

Information on this page was last updated on 3/7/2024.

Robin Sherrington Insider Trading History at Xenon Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2024Sell7,137$46.28$330,300.368,398View SEC Filing Icon  
3/4/2022Sell21,710$30.50$662,155.00View SEC Filing Icon  
5/28/2021Sell6,067$18.81$114,120.2729,141View SEC Filing Icon  
See Full Table

Robin Sherrington Buying and Selling Activity at Xenon Pharmaceuticals

This chart shows Sherrington Robin's buying and selling at Xenon Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals logo
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Read More

Today's Range

Now: $37.25
Low: $36.57
High: $37.75

50 Day Range

MA: $40.25
Low: $37.25
High: $43.75

2 Week Range

Now: $37.25
Low: $27.99
High: $50.99


273,938 shs

Average Volume

351,441 shs

Market Capitalization

$2.81 billion

P/E Ratio


Dividend Yield